作者：阿飞 在2025年全球的IPO市场中，港交所是绝对的"王者"。 今年港股的IPO有多火？根据Wind资讯的统计数据，截至12月18日，港股市场年内共有102家企业完成上市，抛开周末、节假日等非交易日，几乎每两天就 有一只新股完成发行。 至此，2025年港交所IPO募资总额已达2700.86亿港元，时隔4年重回2000亿港元大关，预计全年募资额将超过2800亿港元。 而这一数字也让港交所以绝对优势登顶全球证券交易所募资榜首，远超纽约证券交易所的205亿美元（约合1600亿港元）。全球十大IPO项目中港交所独占4 席，成为全球大型新股的集聚地。 锣声密集到"不够用"，投行人士忙得"没有休息日"，连港交所行政总裁都笑称在海外路演时"饭都吃不上一口"，而这已成为今年港股IPO市场的常态。 政策技术双轮驱动 港股IPO强势回归 香港本地监管层面也在积极优化上市环境。今年5月，香港证监会与港交所联合推出"科企专线"，为特专科技公司及生物科技公司提供保密递交上市申请和 一对一咨询服务。 港股上市审批流程同步优化，监管评估周期缩短至30个工作日内，显著提升了上市效率。 从行业结构来看，科技与企业成为驱动港股IPO市场的 ...

Core Insights - Scientists from the Allen Institute and the Howard Hughes Medical Institute have developed a special protein called iGluSnFR4, which serves as a molecular "glutamate indicator" for real-time observation of neuronal communication in the brain [1][2] - This breakthrough aids in deciphering the hidden "language" of the brain and enhances understanding of its complex neural circuitry [1] Group 1: Technological Advancements - iGluSnFR4 addresses the challenge of previously only being able to record signals emitted by neurons, allowing scientists to "hear" the input signals that neurons receive [2] - The protein is highly sensitive to glutamate, enabling the detection of the weakest input signals between neurons, thus providing new pathways for analyzing the complex cascade of electrical activities that support learning, memory, and emotions [2] Group 2: Implications for Neurological Research - Abnormal glutamate signaling is associated with various neurological disorders, including Alzheimer's disease, schizophrenia, autism, and epilepsy [2] - The ability to observe synaptic activity more precisely with iGluSnFR4 allows for deeper investigation into the mechanisms underlying these diseases [2]

Group 1: China-Thailand Economic Cooperation - China is promoting high-quality development, focusing on new productive forces in key areas such as biotechnology, new energy, and artificial intelligence, which aligns with Thailand's "Industry 4.0" strategy, laying a foundation for cooperation between the two countries [1] - In the first half of this year, the bilateral trade volume between China and Thailand reached $76.1 billion, a year-on-year increase of 17%, with China being Thailand's largest trading partner for 12 consecutive years [1] - Thailand's King Vajiralongkorn's state visit to China in November marks a milestone in bilateral relations, coinciding with the 50th anniversary of diplomatic relations [1] Group 2: Thai Investment in China - Thai companies have a long history of investment in China, with Charoen Pokphand Group being the first foreign enterprise to enter China post-reform, currently operating over 600 enterprises in China with direct investments ranging from 120 billion to 180 billion RMB [2] - Thai investments in China are concentrated across various provinces and sectors, evolving from traditional industries like agriculture to high-tech and quality sectors such as food processing, services, finance, logistics, and bioenergy [2] Group 3: Investment Environment in China - The Chinese government is continuously optimizing the investment environment, promoting high-level opening-up and deepening reforms, which includes establishing free trade zones and reducing negative lists for foreign investment [3] - The recently announced "14th Five-Year Plan" emphasizes expanding domestic demand and innovation, which will create new opportunities for international investors, including those from Thailand [3][4] Group 4: Chinese Investment in Thailand - Chinese enterprises are accelerating investments in Thailand, focusing on emerging industries such as new energy vehicles, digital infrastructure, new materials, and biotechnology, aligning with Thailand's industrial strategies [5] - Thailand is enhancing its infrastructure and workforce skills to better accommodate foreign investments, recognizing the importance of a robust ecosystem for attracting investment [5] Group 5: Social Acceptance of Chinese Investment in Thailand - There is a general positive sentiment towards Chinese investment in Thailand, with approximately 20% to 30% of the population having Chinese ancestry, leading to a welcoming attitude towards Chinese enterprises [6] - The cooperation between China and Thailand is mutually beneficial, with Thailand gaining from investments, domestic market growth, and export activities, fostering a win-win situation [6] Group 6: Trade Challenges and Opportunities - In the face of international trade uncertainties, strengthening bilateral ties is crucial for both countries, as highlighted by the recent royal visit from Thailand to China [7] - Thailand can serve as a reliable partner for Chinese enterprises, helping them export products to broader international markets, thus mitigating risks associated with trade challenges [7][8]

万众一芯生物科技有限公司由张家港市本土孵化，是一家专注于生物芯片技术研发与应用，为精准 医学领域提供创新解决方案的高技术企业。公司具备分子诊断试剂、分子医疗器械、微纳生物芯片/微 流控芯片生产制造能力，赋能肿瘤、慢性病等多组学精准诊疗场景，其开发的"基因电子芯片"及相关技 术路线属国际首创。此次签约的精准医学产业智造中心项目总投资5亿元，集总部大脑、智能制造、产 业生态于一体，将建设芯片、仪器、试剂三条核心产线，实现核心技术的自主可控与规模化输出。其 中，研发中试与总部运营中心将承载芯片制造、仪器装配、试剂生产等功能。 铸强精准医学"中国芯"。昨天（12月23日），张家港万众一芯精准医学产业智造中心项目正式签 约。苏州市委副书记、市长吴庆文出席活动。 张家港万众一芯生物科技有限公司董事长胡文闯；苏州市政府秘书长徐本，张家港市主要负责同志 等参加活动。 活动中，万众一芯关键产品及技术成果发布，战略投资协议签约。 ...

今年5月15日，中行昆明东风支行下达云南振途信息科技有限公司1000万元数据产品质押融资授信，这 是在全国率先完成畜牧业数据产品知识产权质押融资的典型案例，"肉牛生理数据要素数据产品"全链路 得以贯通，为解决云南数据产品知识产权确权登记、资产入表、数据知识产权质押贷款等全链路问题， 提供了可复制、可推广的"经开路径"。 "融资难、融资贵、融资慢"是一直以来制约企业发展壮大的"老大难"问题。聚焦企业发展难点，昆明经 开区（自贸试验区昆明片区）配套推出全链条、定制化的金融服务方案，让金融资源精准滴灌园区创新 创业沃土。 加速"知产"变"资产" 同时，搭建知识产权金融公共服务平台，搭载"鹏之翼"评估系统，引进知识产权服务、评估等机构，建 立知识产权质押融资需求响应机制，为辖区企业、金融机构提供知识产权价值评估、合同备案、质押转 让、供需对接等闭环服务，推动知识产权质押融资工作落到实处。此外，利用自贸试验区"试验田"优 势，联合沪滇临港昆明科技城，依托沪滇建立的跨区域登记互认机制，积极推进数据产品确权。 在系列措施的推动下，知识产权质押融资成效显著。今年昆明经开区（自贸试验区昆明片区）共帮助区 内企业放款23笔、融资 ...

Group 1 - The Hong Kong stock market has experienced increased volatility in the fourth quarter, with investors speculating on the potential for a "Christmas rally" similar to the "spring market" in A-shares [1][2] - Despite the potential for a rebound narrative, the actual investment guidance may be limited, as the market is still under supply and demand pressure, and the right-side turning point remains unclear [3][4] - The Hang Seng Index and other major indices have shown signs of fluctuation, with net inflows from southbound funds exceeding 240 billion HKD in the fourth quarter, indicating a shift in market dynamics [2][3] Group 2 - The market is expected to benefit from a favorable macroeconomic environment and a potential easing of overseas liquidity, which could enhance risk appetite and stabilize the Hong Kong stock market [3][4] - Key sectors for investment include upstream resources in the power chain, travel-related stocks, and leading domestic AI companies, which are seen as having significant layout value [1][4][5] - Emerging industries such as solid-state batteries, brain-computer interfaces, and biotechnology are anticipated to gain momentum, supported by the "14th Five-Year Plan" and improving macroeconomic conditions [4][5]

证券代码：603363 证券简称：傲农生物（维权） 公告编号：2025-116 福建傲农生物科技集团股份有限公司 关于部分限售股上市流通的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 ● 本次股票上市类型为其他股份（重整投资转增股份）；股票认购方式为网下，上市股数为447,000,000 股。 本次股票上市流通总数为447,000,000股。 ● 本次股票上市流通日期为2025年12月29日。 重要内容提示： 一、本次限售股上市类型 福建傲农生物科技集团股份有限公司（以下简称"公司"）本次上市流通的限售股类型为财务投资人在公 司重整中取得的转增股份。 2024年11月5日，福建省漳州市中级人民法院（以下简称"漳州中院"或"法院"）裁定受理债权人对公司 的重整申请，并指定上海市锦天城律师事务所担任公司管理人（以下简称"管理人"），具体内容详见公 司于2024年11月6日披露的《关于法院裁定受理公司重整及指定管理人暨公司股票被叠加实施退市风险 警示的公告》（公告编号：2024-193）。 ■ 本次申请上市流通的限售股共 ...

Core Viewpoint - The Hong Kong IPO market is experiencing extreme volatility, with new stocks showing significant divergence in their first-day performances, highlighting a mixed sentiment among investors [1]. Group 1: IPO Performance - On December 23, three new stocks debuted in the Hong Kong market, with Nobikang soaring by 363.75%, marking the highest first-day gain of the year, while Light Health also saw a substantial increase of nearly 160%. In contrast, Hansai Aitai faced a significant drop of 46.25%, nearing a "halving" of its value [1]. - On December 22, four new stocks, including Nanhua Futures, Mingji Hospital, Huashan Biotechnology, and Yinxiang Dahongpao, all experienced declines, with Mingji Hospital recording a 49.46% drop, the largest first-day loss of the year [1]. Group 2: Nobikang Overview - Nobikang specializes in developing and selling monitoring and detection products and solutions for domestic railway operations and electric grid companies, providing integrated hardware and software solutions based on comprehensive AI industry models [3]. - According to Zhaosheng Consulting, Nobikang is the second-largest provider of AI-powered power detection monitoring systems in China, holding a market share of approximately 5.9% in the rail transit sector for 2024 [3]. - Nobikang has achieved profitability, with projected profits of 63.16 million yuan, 88.57 million yuan, 115 million yuan, and 40.08 million yuan for the years 2022 to 2024 and the first half of 2025, respectively [3]. Group 3: Light Health Overview - Light Health provides health-related and insurance solutions in China, ranking 10th in the digital comprehensive health services and health insurance market based on 2024 revenue [4]. - The company has a growing user base, with registered users reaching 155 million, 164 million, 168.1 million, and 168.4 million by the end of 2022, 2023, 2024, and the first half of 2025, respectively [5]. - Light Health's revenue for the years 2022 to 2025 is projected to be 393.6 million yuan, 490 million yuan, 945 million yuan, and 656.1 million yuan, with adjusted net profits of 149.2 million yuan, 146.6 million yuan, 84.4 million yuan, and 51.2 million yuan during the same period [5]. Group 4: Biotechnology Sector Performance - The biotechnology sector, which had previously shown strong performance in the Hong Kong IPO market, is now facing challenges, with companies like Hansai Aitai and Huashan Biotechnology experiencing significant declines in their stock prices [7][8]. - The Hang Seng Biotechnology Index has seen a decline of over 18% since October, contributing to the recent underperformance of biotech IPOs [8].

Core Viewpoint - The Hong Kong IPO market is experiencing extreme volatility, with new stocks showing significant divergence in their first-day performances, highlighting a mixed sentiment among investors [2]. Group 1: IPO Performance - On December 23, three new stocks debuted in the Hong Kong market, with Nobikang surging by 363.75%, marking the highest first-day gain of the year [2][3]. - Easy Health also saw a substantial increase of nearly 160% on its first day [2][3]. - In contrast, Hansai Aitai faced a significant decline, dropping by 46.25%, nearly halving its value [2][4]. - The previous day, four new listings, including Mingji Hospital, experienced declines, with Mingji Hospital recording a 49.46% drop, the largest for the year [5]. Group 2: Company Insights - Nobikang specializes in developing and selling monitoring and detection products for railway and power companies, providing integrated AI solutions for monitoring and operational purposes [6]. - The company is the second-largest provider of AI-powered power detection systems in China, holding a market share of approximately 5.9% in the relevant sector [6]. - Nobikang has achieved profitability, with projected profits of 63.16 million CNY, 88.57 million CNY, 115.36 million CNY, and 40.08 million CNY for the years 2022 to 2025 [7][8]. - Easy Health offers health-related and insurance solutions in China, ranking 10th in the digital health services market based on 2024 revenue [9][10]. - The company has a growing user base, with registered users increasing from 155 million in 2022 to an expected 168.4 million by mid-2025 [10]. Group 3: Market Trends - The biotechnology sector, which previously showed strong IPO performances, is now facing challenges, as evidenced by the poor debut of Hansai Aitai and the subsequent decline of Huashan Biotechnology [11][13]. - The Hang Seng Biotechnology Index has seen a decline of over 18% since October, indicating a broader downturn in the sector [13].

Core Viewpoint - The Hong Kong IPO market is experiencing extreme divergence in the performance of newly listed stocks, with some achieving significant gains while others face substantial losses [1]. Group 1: IPO Performance - On December 23, three new stocks were listed in the Hong Kong market, showcasing a stark contrast in their first-day performance: Nobikang surged by 363.75%, marking the highest gain for a new stock this year, while Laisong Health rose nearly 160%, and Hansi Aitai plummeted by 46.25% [1][4]. - Nobikang's market capitalization reached approximately HKD 14 billion after its debut, despite the significant price increase [6][8]. Group 2: Company Insights - Nobikang specializes in developing and selling monitoring and detection products for railway operations and electric grid companies, providing integrated AI solutions for monitoring and maintenance [5]. - According to Zhaosheng Consulting, Nobikang holds a market share of about 5.9% in the AI-powered power detection and monitoring system sector in China, ranking as the second-largest provider in this field [5]. - Laisong Health offers health-related and insurance solutions in China, ranking 10th in the digital health service market based on projected 2024 revenue [9][10]. Group 3: Financial Performance - Nobikang is projected to achieve profits of CNY 63.16 million, CNY 88.57 million, CNY 115.37 million, and CNY 40.08 million for the years 2022, 2023, 2024, and the first half of 2025, respectively [6]. - Laisong Health's revenue for the years 2022, 2023, 2024, and the first half of 2025 is expected to be CNY 393.6 million, CNY 490 million, CNY 945 million, and CNY 656.1 million, respectively [10]. Group 4: Market Trends - The biotechnology sector, which previously showed strong IPO performance, has seen a decline in the first-day performance of newly listed companies, with Hansi Aitai experiencing a significant drop [12][14]. - The Hang Seng Biotechnology Index has retraced over 18% since October, reflecting a broader downturn in the biotechnology sector [14].